Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125700 | 0.91 | ALDH1A1 (0.38) | NFE2L2ALDH1A1NAMPTHTR6 | |
| SCHEMBL4138207 | 0.91 | NAMPT (0.38) | ALDH1A1NAMPTEGFRGRM4SLC40A1 | |
| SCHEMBL4130748 | 0.87 | POLB (0.36) | ALDH1A1NAMPTSLC40A1 | |
| SCHEMBL4125619 | 0.87 | ALDH1A1 (0.35) | NFE2L2ALDH1A1NAMPTHTR6 | |
| SCHEMBL4125903 | 0.83 | NAMPT (0.38) | NAMPTGRM4SLC40A1 | |
| SCHEMBL4120137 | 0.82 | LIPG (0.32) | NAMPTGRM4 | |
| SCHEMBL16333440 | 0.82 | NFE2L2 (0.44) | NFE2L2ALDH1A1HTR6 | |
| SCHEMBL4132234 | 0.82 | ATM (0.38) | ALDH1A1NAMPTEGFRGRM4 | |
| SCHEMBL4130106 | 0.82 | NFE2L2 (0.41) | NFE2L2HTR6EGFRDHODH | |
| SCHEMBL4117748 | 0.82 | LIPG (0.32) | GRM4SLC40A1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NFE2L2 2670/4885ALDH1A1 1497/4885NAMPT 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.